May 17, 2017 / 12:26 PM / 2 months ago

BRIEF-Health Canada approves Bristol-Myers' opdivo(nivolumab)

1 Min Read

May 17 (Reuters) - Bristol-Myers Squibb Co

* Health Canada approves opdivo (nivolumab) for the treatment of squamous cell carcinoma of the head and neck

* Bristol- Myers Squibb Co says data to support approval was based on Checkmate-141, a phase three clinical trial Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below